Stefania Nobili^*, Daniele Lavacchi^†, Gabriele Perrone^*, Giulio Vicini^†, Renato Tassi^‡1, Ida Landini^*, AnnaMaria Grosso^§, Giandomenico Roviello^*¶, Roberto Mazzanti^‡, Carmine Santomaggio^¶2, Enrico Mini^*¶

Oncology Research, Vol.28, No.3, pp. 237-248, 2020, DOI:10.3727/096504019X15755437099308

Abstract The use of vinorelbine as a single agent or in combination regimens in non-small cell lung cancer (NSCLC) is associated with satisfactory clinical activity. However, the role of vinorelbine-based chemotherapy in chemonaive locally advanced unresectable or metastatic NSCLC patients, according to real-world treatment patterns, has still not been widely explored. Eighty-one patients treated at a single institution were retrospectively analyzed. Thirty-seven received standard first-line single-agent vinorelbine, and 44 received vinorelbine plus platinum drugs, based on physician’s choice; 61.7% were older than 70 years, and 60.5% were affected by 2 comorbidities. Sixty-three patients were evaluable for objective response: 22% achieved partial… More >

Jiayi Huang¹, Xue Bai¹, Xiaofeng Xie¹, Liping Chen¹, Xiaofeng Lan¹, Qiuyi Zhang¹, Lin Song¹, Pengjiao Hong^2,3, Caiwen Du^1,*

Oncologie, Vol.24, No.1, pp. 131-145, 2022, DOI:10.32604/oncologie.2022.019881

Abstract Background: Vinorelbine can be used to treat metastatic breast cancer as a single agent or in combination with other chemotherapy agents, although there is little real-world data for its use, particularly the oral form, in China. The current study aimed to explore the efficacy and safety of oral vinorelbine in patients with metastatic breast cancer in real-world clinical practice. Methods: A total of 194 patients with metastatic breast cancer received oral vinorelbine as a treatment between February 2017 and January 2021 at the National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences… More >